论文部分内容阅读
导火索在全国人民齐心协力抵抗“非典”的关键时期,却有大量“非典”谣言迅速传播,国内上市公司在这场全民动员的“防治非典”中,不经意间也制造了催动短期赢利的股市谣言。谣言的发端始于深市上市公司海王生物点燃的抗非概念的熊熊烈火。4月24日新华社报道说,一种用于预防“非典”的新药——重组人干扰素α-2b喷雾剂近日已获国家
In the critical period when the people of the whole country make concerted efforts to resist the SARS epidemic, a large number of rumors of “SARS” have spread rapidly. In the “prevention and treatment of atypical pneumonia ” by domestic listed companies in this nationwide mobilization, Produced a rumor prompted the short-term profit in the stock market. The origins of the rumor began with the anti-non-concept raging fire lit by Neptunus Biologicals, a listed company in Shenzhen. Xinhua News Agency, April 24 reported that a new drug for the prevention of “SARS” - recombinant human interferon alpha-2b spray has recently been approved by the state